Recent feasibility studies demonstrating the benefits of pharmacological mitofusin activation in ALS have employed three chemically distinct but functionally similar small molecule mitofusin activators that activate both MFN1 and MFN2 through a common allosteric mechanism [87,102,103]. The gene discussed is MFN2; the disease is amyotrophic lateral sclerosis.